Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Richardson PG, et al. Among authors: barlogie b. J Clin Oncol. 2006 Jul 1;24(19):3113-20. doi: 10.1200/JCO.2005.04.7779. Epub 2006 Jun 5. J Clin Oncol. 2006. PMID: 16754936 Clinical Trial.
Multiple myeloma.
Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Anderson KC, et al. Among authors: barlogie b. Hematology Am Soc Hematol Educ Program. 2002:214-40. doi: 10.1182/asheducation-2002.1.214. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446425 Review.
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B. Shaughnessy J, et al. Among authors: barlogie b. Blood. 2003 May 15;101(10):3849-56. doi: 10.1182/blood-2002-09-2873. Epub 2003 Jan 16. Blood. 2003. PMID: 12531801 Free article.
Infection--an underappreciated cause of bone pain in multiple myeloma.
Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, VijayaGopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Desikan R, et al. Among authors: barlogie b. Br J Haematol. 2003 Mar;120(6):1047-50. doi: 10.1046/j.1365-2141.2003.04178.x. Br J Haematol. 2003. PMID: 12648075 Free article.
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. Richardson PG, et al. Among authors: barlogie b. N Engl J Med. 2003 Jun 26;348(26):2609-17. doi: 10.1056/NEJMoa030288. N Engl J Med. 2003. PMID: 12826635 Free article. Clinical Trial.
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Fassas AB, et al. Among authors: barlogie b. Br J Haematol. 2003 Nov;123(3):484-9. doi: 10.1046/j.1365-2141.2003.04646.x. Br J Haematol. 2003. PMID: 14617011 Free article.
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Jagannath S, et al. Among authors: barlogie b. Cancer. 2005 Mar 15;103(6):1195-200. doi: 10.1002/cncr.20888. Cancer. 2005. PMID: 15690325 Free article.
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Xiao H, Esseltine D, Schenkein D, Anderson KC; SUMMIT Investigators. Richardson PG, et al. Among authors: barlogie b. Blood. 2005 Nov 1;106(9):2977-81. doi: 10.1182/blood-2005-02-0691. Epub 2005 Jul 14. Blood. 2005. PMID: 16020506 Free article. Clinical Trial.
696 results